QURE uniQure

Filed: 7 May 21, 5:11pm











Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 6, 2021


uniQure N.V.

(Exact Name of Registrant as Specified in Charter)


The Netherlands 001-36294 N/A
(State or Other
Jurisdiction of Incorporation)
File Number)
 (IRS Employer
Identification No.)


Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands
(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code: +31-20-566-7394


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, par value €0.05 per shareQUREThe Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 8.01Other Events.


As previously announced, on June 24, 2020, uniQure biopharma BV, a wholly owned subsidiary of uniQure N.V. (the “Company”), entered into a commercialization and license agreement (the “Agreement”) with CSL Behring LLC (“CSL Behring”) providing CSL Behring exclusive global rights to etranacogene dezaparvovec, the Company’s investigational gene therapy for patients with hemophilia B (the “Transaction”).


On May 6, 2021, the Company issued a press release announcing that the closing of the Transaction became effective on May 6, 2021 upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on May 5, 2021. Pursuant to the Agreement, the Company will receive a $450 million cash payment from CSL Behring by May 13, 2021 and will be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones. The Company will also be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of product sales.


The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01Financial Statements and Exhibits.


(d)            Exhibit


Exhibit No.Description
99.1Press Release of uniQure N.V. dated May 6, 2021.
104Cover Page Interactive Data File (embedded with the Inline XBRL document).





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: May 7, 2021By:/S/ MATTHEW KAPUSTA
  Matthew Kapusta
  Chief Executive Officer and Chief Financial Officer